CLINICAL_TRIALS trial_result · 2015-12-22

Clinical Trial Update: LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2 [Phase 3]

Phase 3 trial update assessing LDL-C reduction with PCSK9 monoclonal antibody plus statin therapy in hyperlipidemia.

Upgrade for the full analysis, importance score, and drug timeline.

Sponsor: Amgen | Conditions: Hyperlipidemia | Phase 3 | Status: COMPLETED | Results posted: 2015-12-22